511 related articles for article (PubMed ID: 31093657)
1. Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial.
Morrow DA; Velazquez EJ; DeVore AD; Prescott MF; Duffy CI; Gurmu Y; McCague K; Rocha R; Braunwald E
Eur Heart J; 2019 Oct; 40(40):3345-3352. PubMed ID: 31093657
[TBL] [Abstract][Full Text] [Related]
2. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
DeVore AD; Braunwald E; Morrow DA; Duffy CI; Ambrosy AP; Chakraborty H; McCague K; Rocha R; Velazquez EJ;
JAMA Cardiol; 2020 Feb; 5(2):202-207. PubMed ID: 31825471
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
[TBL] [Abstract][Full Text] [Related]
4. Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF.
Zile MR; O'Meara E; Claggett B; Prescott MF; Solomon SD; Swedberg K; Packer M; McMurray JJV; Shi V; Lefkowitz M; Rouleau J
J Am Coll Cardiol; 2019 Feb; 73(7):795-806. PubMed ID: 30784673
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial.
Velazquez EJ; Morrow DA; DeVore AD; Ambrosy AP; Duffy CI; McCague K; Hernandez AF; Rocha RA; Braunwald E
Am Heart J; 2018 Apr; 198():145-151. PubMed ID: 29653636
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial.
Berardi C; Braunwald E; Morrow DA; Mulder HS; Duffy CI; O'Brien TX; Ambrosy AP; Chakraborty H; Velazquez EJ; DeVore AD;
JACC Heart Fail; 2020 Oct; 8(10):859-866. PubMed ID: 32919915
[TBL] [Abstract][Full Text] [Related]
7. Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure.
Morrow DA; Velazquez EJ; Desai AS; DeVore AD; Lepage S; Park JG; Sharma K; Solomon SD; Starling RC; Ward JH; Williamson KM; Zieroth S; Hernandez AF; Mentz RJ; Braunwald E
J Am Coll Cardiol; 2024 Mar; 83(12):1123-1132. PubMed ID: 38508844
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial.
Berg DD; Braunwald E; DeVore AD; Lala A; Pinney SP; Duffy CI; Gurmu Y; Velazquez EJ; Morrow DA
JACC Heart Fail; 2020 Oct; 8(10):834-843. PubMed ID: 32800511
[TBL] [Abstract][Full Text] [Related]
9. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial.
Berg DD; Samsky MD; Velazquez EJ; Duffy CI; Gurmu Y; Braunwald E; Morrow DA; DeVore AD
Circ Heart Fail; 2021 Feb; 14(2):e007034. PubMed ID: 33530704
[TBL] [Abstract][Full Text] [Related]
11. Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure).
O'Meara E; Prescott MF; Claggett B; Rouleau JL; Chiang LM; Solomon SD; Packer M; McMurray JJV; Zile MR
Circ Heart Fail; 2018 May; 11(5):e004446. PubMed ID: 29748349
[TBL] [Abstract][Full Text] [Related]
12. Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction.
Fudim M; Sayeed S; Xu H; Matsouaka RA; Heidenreich PA; Velazquez EJ; Yancy CW; Fonarow GC; Hernandez AF; DeVore AD
Circ Heart Fail; 2020 Apr; 13(4):e006645. PubMed ID: 32248695
[TBL] [Abstract][Full Text] [Related]
13. Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial.
Chandra A; Lewis EF; Claggett BL; Desai AS; Packer M; Zile MR; Swedberg K; Rouleau JL; Shi VC; Lefkowitz MP; Katova T; McMurray JJV; Solomon SD
JAMA Cardiol; 2018 Jun; 3(6):498-505. PubMed ID: 29617523
[TBL] [Abstract][Full Text] [Related]
14. Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial.
Butt JH; Ibrahim W; Dewan P; Desai AS; Køber L; Prescott MF; Lefkowitz MP; Rouleau JL; Solomon SD; Zile MR; Packer M; Jhund PS; McMurray JJV
Circ Heart Fail; 2023 Mar; 16(3):e010111. PubMed ID: 36943907
[TBL] [Abstract][Full Text] [Related]
15. Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF.
Myhre PL; Prescott MF; Murphy SP; Fang JC; Mitchell GF; Ward JH; Claggett B; Desai AS; Solomon SD; Januzzi JL
JACC Heart Fail; 2022 Feb; 10(2):119-128. PubMed ID: 35115085
[TBL] [Abstract][Full Text] [Related]
16. Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex.
Mitchell GF; Solomon SD; Shah AM; Claggett BL; Fang JC; Izzo J; Abbas CA; Desai AS;
Circ Heart Fail; 2021 Mar; 14(3):e007891. PubMed ID: 33663237
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists.
Ambrosy AP; Braunwald E; Morrow DA; DeVore AD; McCague K; Meng X; Duffy CI; Rocha R; Velazquez EJ;
J Am Coll Cardiol; 2020 Sep; 76(9):1034-1048. PubMed ID: 32854838
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.
Gaziano TA; Fonarow GC; Claggett B; Chan WW; Deschaseaux-Voinet C; Turner SJ; Rouleau JL; Zile MR; McMurray JJ; Solomon SD
JAMA Cardiol; 2016 Sep; 1(6):666-72. PubMed ID: 27438344
[TBL] [Abstract][Full Text] [Related]
19. Sleep Outcomes From AWAKE-HF: A Randomized Clinical Trial of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.
Owens RL; Birkeland K; Heywood JT; Steinhubl SR; Dorn J; Grant D; Fombu E; Khandwalla R
J Card Fail; 2021 Dec; 27(12):1466-1471. PubMed ID: 34428592
[TBL] [Abstract][Full Text] [Related]
20. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]